What is Biofortuna?
Biofortuna operates as a premier contract development and manufacturing organization (CDMO) specializing in critical areas such as assay development, cell line quality control, and comprehensive laboratory services. The company provides a suite of solutions, including molecular and immunoassay development, lyophilisation, and advanced controlled storage. Biofortuna serves a diverse clientele within the life science industry, particularly innovators seeking specialized support to expedite their diagnostic projects. Leveraging state-of-the-art facilities and a stringent commitment to quality, Biofortuna is instrumental in mitigating development risks and accelerating the time-to-market for its clients' groundbreaking innovations.
How much funding has Biofortuna raised?
Biofortuna has raised a total of $14.9M across 7 funding rounds:
Other Financing Round
$1.6M
Other Financing Round
$2M
Other Financing Round
$3.3M
Unspecified
$2M
Unspecified
$2.3M
Unspecified
$1.6M
Unspecified
$2.1M
Other Financing Round (2010): $1.6M with participation from Catapult Ventures and Enterprise Ventures
Other Financing Round (2012): $2M led by Enterprise Ventures, Catapult Ventures, Foresight Group, and Merseyside Special Investment Fund
Other Financing Round (2012): $3.3M supported by Merseyside Special Investment Fund, Catapult Ventures, and Foresight Group
Unspecified (2013): $2M featuring Enterprise Ventures, Catapult Ventures, Foresight Group, and Merseyside Special Investment Fund
Unspecified (2015): $2.3M backed by Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund, and Foresight Group
Unspecified (2016): $1.6M with participation from Catapult Ventures and EV Tech
Unspecified (2017): $2.1M, investors not publicly disclosed
Key Investors in Biofortuna
Enterprise Ventures
Enterprise Ventures, operating within the Investment Banking industry, is a Manchester-based firm known for its investment activities. It is part of the EV Group, which focuses on providing capital and strategic support to businesses.
Catapult Ventures
Catapult Ventures is an investment firm specializing in tailored solutions for entrepreneurs and business owners, aiming to unlock potential and support client ambitions through strategic partnerships and growth-focused capital.
Merseyside Special Investment Fund
Merseyside Special Investment Fund (MSIF) is dedicated to empowering SMEs in the North West of England, offering business planning, funding advice, and access to angel networks through its fund manager, River Capital.
What's next for Biofortuna?
The substantial enterprise-level funding Biofortuna has attracted indicates a company poised for significant scaling and expansion. This capital infusion is likely to fuel advancements in its service offerings, potentially broadening its capacity for complex assay development and manufacturing. Furthermore, the strategic investments suggest a focus on enhancing its technological infrastructure and expanding its market reach within the competitive life sciences sector. Biofortuna is well-positioned to solidify its role as a key partner for diagnostic and biotech innovators.
See full Biofortuna company page
